Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells by Farace, Cristiano et al.
RESEARCH ARTICLE
Microenvironmental Modulation of Decorin
and Lumican in Temozolomide-Resistant
Glioblastoma and Neuroblastoma Cancer
Stem-Like Cells
Cristiano Farace1☯‡*, Jaime Antonio Oliver2☯‡, Consolacion Melguizo2,3,4,
Pablo Alvarez2,4, Pasquale Bandiera1, Ana Rosa Rama2,4,5, Giulia Malaguarnera6,
Raul Ortiz2,4,5, Roberto Madeddu1,7‡*, Jose Prados2,3,4‡
1 Department of Biomedical Sciences, University of Sassari, Sassari, Italy, 2 Institute of Biopathology and
Regenerative Medicine (IBIMER), Granada, Spain, 3 Department of Anatomy and Embryology, University of
Granada, Granada, Spain, 4 Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada,
Granada, Spain, 5 Department of Health Science, University of Jaén, Jaén, Spain, 6 Research Center "The
Great Senescence", University of Catania, Catania, Italy, 7 National Institute of Biostructures and Biosystem
(INBB), Rome, Italy
☯ These authors contributed equally to this work.
‡RM and JP also contributed equally to this work and are listed alphabetically. CF and JAO are also listed
alphabetically.
* cfarace@uniss.it (CF); rmadeddu@uniss.it (RM)
Abstract
The presence of cancer stem cells (CSCs) or tumor-initiating cells can lead to cancer recur-
rence in a permissive cell–microenvironment interplay, promoting invasion in glioblastoma
(GBM) and neuroblastoma (NB). Extracellular matrix (ECM) small leucine-rich proteogly-
cans (SLRPs) play multiple roles in tissue homeostasis by remodeling the extracellular
matrix (ECM) components and modulating intracellular signaling pathways. Due to their
pan-inhibitory properties against receptor tyrosine kinases (RTKs), SLRPs are reported to
exert anticancer effects in vitro and in vivo. However, their roles seem to be tissue-specific
and they are also involved in cancer cell migration and drug resistance, paving the way to
complex different scenarios. The aim of this study was to determine whether the SLRPs
decorin (DCN) and lumican (LUM) are recruited in cell plasticity and microenvironmental
adaptation of differentiated cancer cells induced towards stem-like phenotype. Floating
neurospheres were generated by applying CSC enrichment medium (neural stem cell
serum-free medium, NSC SFM) to the established SF-268 and SK-N-SH cancer cell lines,
cellular models of GBM and NB, respectively. In both models, the time-dependent synergis-
tic activation of DCN and LUM was observed. The highest DCN and LUMmRNA/protein
expression was detected after cell exposure to NSC SFM for 8/12 days, considering these
cells as SLRP-expressing (SLRP+) CSC-like. Ultrastructural imaging showed the cellular
heterogeneity of both the GBM and NB neurospheres and identified the inner living cells.
Parental cell lines of both GBM and NB grew only in soft agar + NSC SFM, whereas the sec-
ondary neurospheres (originated from SLRP+ t8 CSC-like) showed lower proliferation rates
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than primary neurospheres. Interestingly, the SLRP+ CSC-like from the GBM and NB neuro-
spheres were resistant to temozolomide (TMZ) at concentrations >750 μM. Our results sug-
gest that GBM and NB CSC-like promote the activation of huge quantities of SLRP in
response to CSC enrichment, simultaneously acquiring TMZ resistance, cellular heteroge-
neity, and a quiescent phenotype, suggesting a novel pivotal role for SLRP in drug resis-
tance and cell plasticity of CSC-like, allowing cell survival and ECM/niche modulation
potential.
Background
Glioblastoma (GBM) and neuroblastoma (NB) are the most common and lethal nervous sys-
tem malignant cancers in adult and pediatric patients, respectively. The World Health Organi-
zation considers GBM the most aggressive astrocytoma, and it can develop into secondary
GBM from low-grade gliomas, or de novo with rapid progression to death [1]. In contrast, NB
mainly arises from neural crest cells as a neuroendocrine cancer of the sympathetic nervous
system, and 60% of pediatric patients show metastatic disease at diagnosis [2]. Although temo-
zolomide (TMZ)–an alkylating agent which induces cell death by whole DNA alkylation/meth-
ylation in guanine residues–in combination with other drugs or radiotherapy represent a first-
line treatment increasing the overall survival (OS) of patients with GBM or NB [3, 4], drug
resistance and cancer progression are common. Because GBM is highly invasive in the brain
and NB tends to invade other organs, patient OS remains poor (< 1.5 years in GBM patients
and 4 years in NB patients) [5, 6].
Treatment failure in cancer patients has previously been related to cancer stem cell (CSC)
subpopulations, which ensure the maintenance of cancer heterogeneity, and these CSC sub-
populations are more resistant to selective drugs through multiple concerted steps of self-
renewal and differentiation [7–9]. Metastasis and cancer recurrence are also linked to the
behavior of CSCs, including their quiescent phenotype, migratory ability, and evasion of the
immune system [10]. Abundant research suggests that cells stem-like cells are equipped with
innate machinery that protects them from radio/chemotherapy [11, 12]. This includes stem-
related mechanisms, such as protective cell niches and changes in the expression of genes
involved in the regulation of the cell cycle, DNA repair, drug metabolism, and drug efflux [13].
The drug resistance and cellular invasion potential of CSCs also increase at the reversible epi-
thelial-to-mesenchymal phenotypic transition (EMT) [14, 15], which recapitulates the EMT in
normal organogenesis and development [16, 17].
Several microenvironmental signals, including the reorganization of the extracellular matrix
(ECM), hypoxia, and autocrine/paracrine factors, can determine stem and cancer cell fates
[18–25], and trigger or inhibit EMT processes [26, 27]. Therefore, ECM glycoproteins and pro-
teoglycans that are capable of modifying both the ECM environment and intracellular signaling
pathways are of utmost importance in the cancer microenvironment [28–30]. The small
leucine-rich proteoglycans (SLRPs), sharing strategically conserved domains, represent a clear
example of the abovementioned concept. The leucine-rich protein core (40–50 kDa) bind to a
number of growth factors (GF) and membrane receptors, whereas ramification of glycosami-
noglycanic side chains are involved in ECM–collagen assembly and also in membrane receptor
binding. Interestingly, in spite of their pan-inhibitory properties against receptor tyrosine
kinases (RTKs) and cancer growth pathways, the “guardian from the matrix” decorin (DCN)
and lumican (LUM) SLRPs could exert anticancer effects in vivo and in vitro [31–33].
SLRPs and Drug-Resistant Cancer Stem-Like Cells
PLOS ONE | DOI:10.1371/journal.pone.0134111 July 31, 2015 2 / 18
However, recent studies have shed light on newly identified tissue-specific properties of both
DCN and LUM in normal tissues and in the malignant cancer microenvironment. As reported
by other authors, the partial glioma inhibition by DCN in gene therapy experiments in rats
brings with it a marked reduction of microglial cells infiltration [34], which could affects cancer
inhibition in vivo. DCN also enhances the evasion of the immune system and muscle invasion
in prostate cancer in vivo [35], and exerts unexpected protective and antiapoptotic effects in
glioma cell lines under hypoxic conditions [36]. In oral malignant squamous cell carcinoma
cells, the nuclear localization of DCN seems to enhance cellular invasion via the nuclear epider-
mal growth factor receptor (EGFR) pathway [37, 38], whereas in osteosarcoma cells, DCN-
mediated growth arrest is avoided via the protracted activation of membrane EGFR [39]. Clini-
cally, DCN has been proposed as regulator of chemoresistant mechanism in oral cancer [40]
and related to drug resistance and reduced survival in GBM patients [41]. Similarly to DCN,
LUM is reported to mediate tumor suppression. However, LUM is expressed in high-grade
pancreatic cancers with a low degree of differentiation [42] and in GBM patients, as well. LUM
also inhibits cell adhesion and promotes the migration of osteosarcoma cells by regulating the
transforming growth factor β2 (TGF-β2)/SMAD2 pathway [43], and a 70-kDa LUM proteogly-
can seems to enhance cancer cell proliferation and inhibits the migration of pancreatic cancer
cells. Moreover, together to DCN, LUM was upregulated in cisplatin-resistant head and neck
cancer cells [44].
It is noteworthy that SLRPs are expressed in stem cell niches in the chick embryo [45], in
cerebral endothelial cells [46], in progenitors of various cell types [47], and in a NB cell subpop-
ulation unresponsive to nerve-growth-factor-mediated neurite growth [48]. DCN derived from
astrocytes also inhibits neural stem cell/progenitor cell differentiation towards a neuron-like
cell structure [49]. Altering the mechanical characteristics of three-dimensional (3D) collagen
matrices, SLRPs are recruited during the ontogenic (developmental) EMT [50], cell precursor
migration and differentiation [51], and wound healing/tissue repair in response to central ner-
vous system injury and inflammation [52]. In this context, it is conceivable that the small DCN
and LUM proteoglycans play a role in the biology of CSCs of nervous system origin. To this
end, we investigated the involvement of DCN and LUM in GBM and NB CSC-like models,
simulating the phenomena of anchorage loss and the detachment of differentiated tumor cells
that underlie the EMT process, and their relationship to CSC-like behavior and the cell
response to TMZ. In this study, we report for the first time the massive synergistic expression
of DCN and LUM SLRPs in GBM and NB cell lines subjected to floating 3D neurosphere-
based CSC-like enrichment. Neurosphere micrographs highlight the stem-like heterogeneity
and cell polarization of the 3D NB and GBMmodels. Moreover, SLRP+ NB and GBM CSC-like
isolated from the neurospheres showed lower proliferation rates, less apoptosis, and greater
drug resistance than the parental cell lines, suggesting pivotal and synergistic roles for DCN
and LUM in the TMZ resistance, survival, and maintenance of quiescent, slow-cycling, CSC-
like subpopulations.
Methods
Cell lines and CSC enrichment
In this study, two established GBM and NB cell lines were enrolled. The SK-N-SH cell line is a
commercial epithelial cell line originally derived from bone marrow metastasis of a 4-years-
old Caucasian female suffering with NB, and it was previously enriched in CSC-like. In con-
trast, SF-268 is a nonepithelial cell line derived from a high-grade anaplastic astrocytoma,
which has never been used for CSC-like enrichment. The established SK-N-SH (from the
American Type Culture Collection) and SF-268 cancer cell lines (kindly provided by the
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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Instrumentation Scientific Center, Granada University) were routinely maintained as adher-
ent cultures (monolayers) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin, in a humidified atmosphere at
37°C with 5% CO2. Confluent cells were detached in 5 ml of phosphate-buffered saline (PBS)–
ethylenediaminetetraacetic acid (EDTA) at 37°C for 10 min, washed twice in PBS, and subcul-
tured as monolayers. CSC enrichment of the cancer cell lines was performed by generating
neurospheres in neural stem cell serum-free medium (NSC SFM) [53, 54], containing Knock-
Out DMEM/F12 plus 20 μg/ml basic fibroblast growth factor (bFGF), 20 μg/ml epidermal
growth factor, 1× StemPro Neural Supplement (Invitrogen, Paisley, UK), 1% L-glutamine, and
1% penicillin/streptomycin. NSC SFM was replaced every 2 days after mild centrifugation of
the neurospheres.
RNA extraction and quantitative reverse transcription (qRT)–PCR
The expression of DCN and LUMmRNAs was assessed in t0 cells and neurospheres after 4
(t4), 8 (t8), and 12 days (t12) of CSC enrichment. The parental cell lines in DMEM were used as
the control (t0). RNA was extracted with the RNeasy Mini Kit (Qiagen, MD, USA) and quanti-
fied with a Nanodrop spectrophotometer (Thermo Scientific, DE, USA). The RNA (1 μg) from
each sample was reversed transcribed with M-MLV reverse transcriptase (Sigma, Italy),
according to manufacturer’s instructions, and SYBR Green-based amplification (Applied Bio-
systems, Foster City, CA) was performed with the CFX96 Real-Time PCR Detection System
(Bio-Rad, Italy), as previously reported [55]. The PCR cycling program was: 50°C (2 min),
95°C (2 min), 42 cycles of: denaturation at 95°C (30 s), annealing at 56°C (30 s), and extension
at 72°C (40 s), followed by a melting curve analysis (range 56–95°C) with increments of 0.5°C/
5 s to assess the primer specificity. The primer sequences were: forward 50-GGA CCG TTT CAA
CAG AGA GG-30, reverse 50-GAC CAC TCG AAG ATG GCA TT-30 (DCN); forward 50-TGG
AGG TCA ATC AAC TTG AGA A-30, reverse 50-CAA ACG CAA ATG CTT GAT CTT-30 (LUM);
forward 50-CAA GGA GTA AGA CCC CTG GAC-30, reverse 50-TCT ACA TGG CAA CTG TGA
GGA G-30 (glyceraldehyde 3-phosphate dehydrogenase, GAPDH); forward 50-GGC ATC CTC
ACC CTG AAT GA-30, reverse 50-AGG TGT GGT GCC AGA TTT TC-30 (β-actin, ACTB). The
target transcripts were independently normalized to GAPDH and ACTB (housekeeping
genes), and the RNA of the t0 cells was used as the calibration control. The results were
expressed on a logarithmic scale as fold changes (FCs), with the 2–ΔΔCt method.
Western blotting
Whole protein extracts were obtained with the pulsed sonication of cellular pellets in 200 μl of
extraction buffer containing 50 mM Trizma-base, 0,25 mM sucrose, 5 mM EDTA (pH 7.4),
0.5% Triton-X 100 and 1% protease inhibitor cocktail. The protein concentrations were deter-
mined with the Bradford method. The proteins (50 μg) were mixed 1:1 with 2 × Laemmli
buffer, heated at 95°C for 5 min, and loaded onto a 12% denaturing SDS-PAGE gel with the
Kaleidoscope prestained standards. The proteins were separated electrophoretically at a con-
stant voltage (90 V) for 90 min and blotted onto a 0.45 μm nitrocellulose membrane under
semidry conditions with the Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad,
Spain) for 25 min at 200 mA. The membranes were blocked with 5% skim milk in PBS, incu-
bated at 4°C overnight with rabbit polyclonal anti-LUM antibody (diluted 1:100; sc-33785,
Santa Cruz Biotechnology, Santa Cruz, CA) or mouse monoclonal anti-DCN antibody (1:50;
sc-73896, Santa Cruz Biotechnology) in blocking buffer, washed 4 times in washing solution
(0.1% Tween in PBS), incubated at room temperature for 1 h with the appropriate monoclonal
horseradish-peroxidase-conjugated secondary antibody (1:5000; Sigma Aldrich), and washed
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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again in washing solution. The blots were detected with ECLWestern Blotting Detection
Reagents (Amersham; UK). The Molecular Imager VersaDoc MP 4000 system (Bio-Rad, Her-
cules, CA) was used for chemiluminescence visualization. The blots were stripped and incu-
bated with mouse monoclonal anti-β-actin antibody (1:30000; Sigma Aldrich) as the loading
control.
Soft agar cultures
The cell lines were cultured in soft agar to assess their colony or neurosphere formation under
anchorage-independent conditions, in DMEM or NSC SFM. To explore the proliferation of
the SLRP+ CSC-like after CSC enrichment for 8 days (t8 CSC-like), secondary neurospheres
were generated from t8 CSC-like. Briefly, StemPro Accutase Cell Dissociation Reagent (Invitro-
gen) was used to dissociate the t8 neurospheres. A Trypan blue exclusion test was performed
and 5 × 103/ml cells were collected in 2 × DMEM or NSC SFM. The cells were mixed 1:1 with a
prewarmed solution containing 0.6% ultrapure agarose in PBS (0.3% final agar concentration),
seeded in triplicate in six-well plates on 2 ml of solidified 0.6% bottom agar, and incubated in a
humidified atmosphere at 37°C with 5% CO2. The soft agar cultures were photographed daily
under an inverted phase-contrast microscope (Nikon Eclipse TE 2000-S).
Transmission and scanning electron microscopic imaging
Eight-day (t8) neurospheres were collected, washed in PBS, and fixed in 2.5% glutaraldehyde
in 0.1 M PBS (pH 7.4) for 2 h at 4°C. The fixed neurospheres were carefully washed four times
in PBS, postfixed in 1% osmium tetroxide (OsO4) in 0.1 M PBS for 1 h at 4°C, and stored in
PBS at 4°C until embedding. The samples used for transmission electron microscopy (TEM)
were dehydrated in series of increasing acetone concentrations and embedded in epoxy resin
for ultrathin sectioning at 60°C overnight. The ultrathin slices cut with an 8800 Ultratome
(LKB, Bromma, Sweden) were stained with 4% uranyl acetate and lead citrate and viewed on a
Zeiss EM 109–902 transmission electron microscope (Zeiss, Oberchochen Germany). For
scanning electron microscopy (SEM), the postfixed neurospheres were incubated in pure hex-
amethyldisilazane for 1 h at 4°C, dried in a critical point dryer (Polaron, Watford, UK), and
metalized in an S150A Sputter Coater (Edwards, Crawley, UK) for scanning in Quanta 200
(FEI, Eindhoven, The Netherlands) or DSM 962 SEM instruments (Zeiss, Oberchochen,
Germany).
TMZ treatment and MTT assay
Single cells from the monolayers and t8 neurospheres of both cell lines were collected as
described above. Cell viability was tested with Trypan blue exclusion and 5 × 103 cells/well
were seeded in 96-well microtiter plates, in DMEM or NSC SFM. The next day, the medium
was replaced with fresh medium without or with different concentrations of TMZ (25–
1500 μg/ml; Sigma, Madrid, Spain). DMSO was included as the vehicle control. Each condition
was tested in six wells. Three days later, the medium was replaced with fresh medium to pre-
serve TMZ activity. The end-point of the TMZ treatment was established on day 6. Finally, a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was
performed (Sigma). Briefly, 20 μl of MTT/well was added and the plates were incubated at
37°C. After 4 h, the medium was carefully removed and DMSO was added to dissolve the for-
mazan salts. The reactions were measured with a Multiskan EX microplate photometer
(Thermo Scientific, Madrid, Spain) at 570 nm. The TMZ dose–response was expressed as the
percentage (%) inhibition of the cell metabolic activity relative to that of untreated cells and
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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adjusted to the vehicle control. The inhibition of cell growth by TMZ was evaluated in quadru-
plicate experiments.
Statistical analysis
Student’s two-tailed t test was used to determine the statistical significance of the differences in
the TMZ treatment results for the SLRP+ CSC-like and the parental cell lines. The differences
in qPCR gene expression were evaluated with one-way analysis of variance (ANOVA). Statisti-
cal significance was set at p<0.05.
Results
DCN and LUM expression during neurosphere-based CSC enrichment
Neurospheres of both SF-268 and SK-N-SH cell lines acquired regular 3D conformations
resulting from the sustained radial proliferation of most cells, reaching>50 μm after 4 days
(Fig 1A). A qRT–PCR analysis showed that DCN and LUMmRNA expression, with the excep-
tion of LUM in SF-268 t12, increased under CSC enrichment conditions in both cell lines,
showing the highest DCN and LUMmRNA expression values after 8 days (t8). Compared with
the parental cell lines (t0), and considering ACTB as housekeeping gene, GBM CSC-like were
more enriched in LUMmRNA (FCLum = t0: 1; t4: 11.00; t8: 21.70; t12: 9.51) than in DCN
mRNA (FCDcn = t0: 1; t4: 6.32; t8: 17.87; t12: 11.08) (p< 0.01). Similarly, the NB CSC-like
showed higher LUMmRNA levels (FCLum = t0: 1; t4: 29.04; t8: 105.78; t12: 60.12) than DCN
mRNA levels (FCDcn = t0: 1; t4: 23.02; t8: 80.44; t12: 40.22) (p< 0.01; Fig 1B).
The protein analysis showed a clear increase in LUM protein (70-kDa) during CSC enrich-
ment. The highest LUM expression was detected in both SF-268 and SK-N-SH t8 neurospheres
(Fig 1C). By contrast, 40-kDa LUM protein was detected with much less expression that
70-kDa LUM in both SF-268 and SK-N-SH, and especially in t12 (Fig 1C). On the other hand,
we detected a significant increase in DCN (>150-kDa) protein expression in both SF-268 and
SK-N-SH t12 neurospheres while 40-kDa DCN protein was detected very weakly, with a diffi-
cult expression evaluation. According to mRNA results, 8-days SLRP+ CSC-like (t8 CSC-like)
derived from both GBM and NB cell lines were enrolled in further analysis.
Soft agar cultures of SLRP+ CSC-like and parental cell lines
To assess the differences in cell growth between the CSC-like and parental cell lines, the sec-
ondary neurospheres from SLRP+ t8 CSC-like were generated in soft agar and compared with
the parental-cell-derived primary neurospheres. The anchorage-independent soft agar cultures
showed neurosphere colonies in NSC SFM, whereas no or low colonies of parental cells had
grown in the DMEM-based soft agar assay after 22 days (Fig 2A). The primary SK-N-SH neu-
rospheres were larger than the SF-268 neurospheres, reaching> 200 μm after 3 weeks, and had
shown a clearly visible dark core within the 3D structure. The soft agar cultures of t8 GBM and
NB CSC-like (SLRP+) grew as small secondary neurospheres in NSC SFM, and curiously also
as small colonies in DMEM after 30 days (Fig 2B). The secondary neurospheres were smaller
than the primary neurospheres and intrasphere stressed cells (dark cores) were only detectable
in the secondary SF-268 neurospheres after 2 weeks, whereas the secondary SK-N-SH neuro-
spheres maintained a translucent appearance.
Heterogeneic ultrastructures of GBM and NB neurospheres
Ultrastructural imaging with TEM and SEM showed broad cellular heterogeneity in the t8 neu-
rospheres of both cell lines. SEM imaging of the neurosphere surfaces showed more packaged
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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cells in the NB neurospheres than in the GBM neurospheres, whereas the peripheral cells of the
GBM neurospheres had more thin membrane extroflections than the SK-N-SH neurospheres
(Figs 3A, 3B, 4A and 4B). Adjacent electron-dense and electron-lucent cells and sporadic apo-
ptotic cells were observed at the GBM neurosphere peripheries (Fig 3C–3E). The peripheral
cells of the NB neurospheres were polarized, with more OsO4 staining in the cytoplasm than
the inner cells, and contained dense granules, endocytic vesicles, and few membrane extroflec-
tions (Fig 4C–4E). Wide areas of cell death, characterized by membrane blebbing, cell wrin-
kling, apoptotic bodies, and wide nuclear compacted heterochromatin, were observed in the
Fig 1. DCN and LUMmRNA/protein expression in GBM and NB CSC-like enrichments. (A) Neurosphere generation from SF-268 and SK-N-SH cell
lines. Bar, 50 μm. (B) Expression of DCN and LUMmRNAs in CSC enrichment cultures. qRT–PCR results were normalized to ACTB and graphed as relative
fold changes (FCs) between neurospheres at different time points (t4, t8, and t12) and adherent t0 cells with the 2
–ΔΔCt method. All DCN and LUM FC values
for the neurospheres were statistically significant (*p < 0.01). (C) Western blotting analysis of DCN and LUM. β-Actin was used as the loading control. Total
DCN and LUM levels were higher in the neurospheres than in the adherent cells of both cell lines. A 70-kDa LUM isoform was upregulated in the
neurospheres of both cell lines, with the highest expression in the t8 neurospheres. Adherent SF-268 cells showed basal expression of the 37-kDa LUM core
protein.
doi:10.1371/journal.pone.0134111.g001
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Fig 2. Soft agar cultures of SLRP+ CSCs and parental cancer cell lines. (A) Primary soft agar neurospheres from the parental cell lines. Absence of
colonies formation in semisolid DMEM (22 days) and neurosphere formation in semisolid NSC SFM (14 and 22 days). (B) Secondary soft agar neurospheres
from SLRP+ CSC-like isolated from t8 neurospheres. Neurospheres were generated in both semisolid DMEM and semisolid NSC SFM (14 and 22 days),
suggesting the slow cycling behavior of the CSC-like and residual death evasion activity in the DMEM-grown secondary neurospheres. Bar, 50 μm.
doi:10.1371/journal.pone.0134111.g002
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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Fig 3. Representative images of GBM t8 neurospheres. (A) SEM image of a whole SF-268 neurosphere (1000×). (B) SEM image of the neurosphere
surface (2200×). (C–J), TEM images of inner and peripheral neurospheres. Details of thin membrane extroflection (C–D), interactions between electron-
dense and electron-lucent cells (E), details of cell–cell adhesion (F), suffering sites in the inner spheres, with necrotic (G) and apoptotic (H) cells, living cells,
and details of the mitochondrial apparatus in the inner spheres (I, J). Note the apoptotic cells at the periphery of a neurosphere (D) and the living cells close to
the suffering sites (I). Bar: (C–E) and (G–I), 5 μm; (F and J), 1 μm.
doi:10.1371/journal.pone.0134111.g003
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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middle of the neurospheres of both cell lines (Figs 3G, 3H, 4G and 4H). However, active mito-
sis and living cells close to the inner stressed sites were also observed, in both the GBM and NB
neurospheres (Figs 3G, 3I, 3J, 4F and 4J). Interestingly, these microenvironment-resistant cells
in the hypoxic neurosphere core showed indented nuclei, large amounts of euchromatin and
clearly visible mitochondrial apparatus.
Fig 4. Representative images of NB t8 neurospheres. (A) SEM image of whole SK-N-SH neurosphere
(950×). (B) SEM imaging of neurosphere surface (3000×). (C–J) TEM images of inner and peripheral
neurosphere. Details of the cell vesicles, cell polarization, and detachment (C–E), living cells in the inner
neurospheres and details of the mitochondrial apparatus (F), suffering sites in the inner spheres, with necrotic
(G) and apoptotic cells (H and I), and an intrasphere mitotic event (J). Bar: (C–J), 5 μm.
doi:10.1371/journal.pone.0134111.g004
SLRPs and Drug-Resistant Cancer Stem-Like Cells
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TMZ treatment and MTT assay of SRLP+ CSC-like and parental cell
lines
Low-range TMZ concentrations (0–500 μM) did not induce significant differences in the meta-
bolic activities of the SF-268 parental cells and SRLP+ t8 CSC-like. As shown in Fig 5A, the met-
abolic activity of the parental cells ranged from 76.14% to 100% (94.63% ± 7.10%), whereas
metabolic activity of SRLP+ t8 CSC-like ranged from 80.71% to 100% (88.22% ± 5.43%). Higher
concentrations of TMZ (750–1500 μM) induced significant differences between the SLRP+ t8
CSC-like and the parental cell line. At these concentrations, the metabolic activity of the SF-
268 parental cell line ranged from 38.99% to 58.86% (51.80% ± 7.59%), whereas that of SF-268
SRLP+ t8 CSC-like ranged from 79.09% to 79.64% (78.94% ± 0.45%) (p<0.05). The SF-268
parental IC50 was around 1250 μM, and did not reach the IC50 of the SF-268 SRLP
+ t8 CSC-
like.
At low and high concentrations, TMZ induced significant differences in the metabolic activ-
ities of the SK-N-SH parental cells and the SRLP+ t8 CSC-like. As shown in Fig 5B, the meta-
bolic activity of cells treated with 0–500 μMTMZ ranged from 75.08% to 100% (88.41% ±
6.70%) for parental cells and from 66.86% to 100% (74.70% ± 10.84%) for SRLP+ t8 CSC-like
(p<0.05). However, in cells treated with 750–1500 μMTMZ, the metabolic activity switched
and ranged from 42.91% to 68.56% (54.96% ± 9.61%) for parental cells and from 63.92% to
70.61% (66.64% ± 2.50%) for SRLP+ t8 CSC-like (p<0.05). The IC50 in SK-N-SH parental cells
was around 1250 μM, and did not reach the IC50 of the SK-N-SH t8 SRLP
+ CSC-like.
Discussion
The stem cell theory of cancer is a new understanding of cancer development that considers
oncogenesis to be aberrant organogenesis [56]. Because CSC-like are present in cancer as
tumor-initiating cells and circulating tumor cells, they might interact with and react to the CSC
niche, which may modulate the cell fates, contributing to cancer tissue heterogeneity and drug
resistance [57]. This plasticity facilitates anchorage loss and cell motility, generating circulating
tumor cells via the EMT in an instructive microenvironment. Different CSC subpopulations
have been found within the same tumor [58], dispelling all doubt about the roles of CSCs in
cancer heterogeneity and microenvironment modulation, and consequently in drug resistance
[59, 60]. Several previous studies reported SLRP proteins in breast [61], pancreatic [62], colo-
rectal [63], uterine cervical [64], prostate [30], and lung cancers [65], among others, highlight-
ing the controversial roles of DCN and LUM in cancer biology. Our results provide the first
evidence of the relevance of DCN and LUM to CSC biology, demonstrating significantly
increased mRNA and protein levels of both SLRPs in GBM and NB CSC-like. However, while
LUMmRNA and protein increased in t8 neurospheres, DCN mRNA increased at t8 and DCN
protein at t12. This fact could be explained by differences between DCN and LUM in intra-
sphere trapping and maybe by CSC specific post-transcriptional regulation mechanisms which
are still unknown. In addition, the influence of growth factors and their receptors, such those
of EGF and TGF-β1, in DCNmodulation and trafficking has been showed in adult cells [66,
67], suggesting putative crosstalk of DCN and growth factors pathways in CSC, which deserve
further mechanistic investigations.
The 3D tumorsphere cultures in conditioned serum-free media, which constitute a method-
ological evolution of the neurosphere cultures used in neural stem and progenitor cell research
[68–70], are considered representative in vitro cancer models useful in the CSC-like enrich-
ment of primary [71–75] and established cancer cell lines [76, 77]. Here, this model was used
to achieve neurosphere-based serum-free CSC enrichment of human GBM and NB cancer cell
lines, enhancing cell plasticity through cell dedifferentiation towards a stem-like phenotype.
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Fig 5. MTT assay after TMZ treatment. (A) SF-268 adherent cells versus SF-268 SLRP+ t8 CSC-like. (B)
Adherent SK-N-SH cells versus SK-N-SH SLRP+ t8 CSC-like. Cell growth inhibition by low doses of TMZ (0–
500 μM) was greater in the t8 CSCs-like than in the parental cell lines, with significance in SK-N-SH cells
(*p < 0.05, Fig 5B). In contrast, cell growth inhibition by high doses of TMZ at, corresponding to
pharmacological doses (> 750 μM), was greater in the parental cells than in the t8 CSCs-like cells in the CSC
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Neurospheres of both cell lines showed heterogeneity in their cell size, ultrastructure, and pro-
liferation, confirming the relevance of CSC-like in the maintenance of cell heterogeneity. Ultra-
structural imaging of the neurospheres revealed both electron-dense and electron-lucent cells,
which implies the presence of cells at different stages of differentiation, with peripheral cells
enriched in endocytic vesicles, probably for vesicle-mediated internalization of DCN by RTK
[66], and cell-specific signs of differentiation, particularly dense granules in NB cells and thin
membrane extroflections in GBM cells. The presence of living inner-neurosphere cells after
CSC enrichment for 8 days suggest that only a fraction of the inner cells evade apoptosis or
necrosis in the hypoxic microenvironment of the neurosphere core. Interestingly, CSC-like
with the highest levels of DCN and LUMmRNA, isolated from heterogenic t8 neurospheres,
switched towards a quiescent phenotype in the soft-agar-grown secondary neurospheres,
showing reduced cell proliferation and apoptosis. The SLRP+ CSC-like still partly grew as loose
cell aggregates in the DMEM soft agar-grown secondary cultures, suggesting residual CSC-like
evasion of cell death. Moreover, the SLRP+ CSC-like acquired TMZ resistance, as shown in an
MTT-based assay. Despite the higher proliferation rate of the parental cell lines vis-à-vis the
slow cycling of the CSC-like at low doses of TMZ, significant resistance to high-dose TMZ was
observed in the SLRP+ CSC-like of both cell lines, which could be a microenvironment-related
phenomenon and/or attributable to the overexpression of multidrug-resistance or DNA repair
genes in the CSC-like [78, 79]. On the other hand, the lower cell viability of CSC-like than
parental cells at low TMZ concentrations might be result of underestimation due to the func-
tion of the ABC transporters in pumping out of the cells the MTT molecules.
Interestingly, quiescent CSC-like seem to be involved in the EMT and the mesenchymal–
epithelial transition (MET) and in cancer dormancy, which have been closely associated with
drug resistance [80]. Our data, showing the anchorage-independent growth, resistance to high
concentrations of TMZ, and lower cell proliferation of t8 CSC-like relative to those of the
parental cell lines, suggest that GBM and NB cells can acquire a quiescent stem-like phenotype.
These results indicate a putative relation between DCN and cell quiescence which has been
observed in other cellular models [81], and that SLRPs members, in particular the LUM pro-
teoglycan, could play a role in the CSC microenvironment and in cancer dormancy [82]. How-
ever, further studies of the pathophysiologic role of DCN and LUM in CSC will be necessary.
The tumor mass is mainly composed of differentiated tumor cells. In metastatic cancer, the
MET program fosters epithelial-like cell proliferation of homed circulating tumor cells. Previ-
ous studies have shown that DCN inhibits glioma growth and cell differentiation. In contrast,
DCN has been reported to play protective and antiapoptotic roles in glioma cell lines exposed
to hypoxic microenvironments. Inherent to this study, the formation of 3D neurospheres nec-
essarily generates a hypoxic microenvironment in the inner regions, which is why some cells
inside the neurospheres undergo apoptosis/necrosis. It is well known that hypoxia plays a criti-
cal role in CSCs and niche maintenance, promoting hypoxia-inducible factor (HIF)-dependent
reprogramming of the differentiated tumor cells towards a CSC-like phenotype [83]. Interest-
ingly, HIF downstream effectors inhibit NB cell differentiation and were reported to co-localize
with neural crest and stem cell markers in the perivascular niche in NB biopsy samples [84].
Here, we report the presence of both suffering and living cells in the hypoxic microenviron-
ment of the inner neurosphere, and that the living inner neurosphere cells are resistant to
TMZ. Hence, according to the studies abovementioned and the proof-of-concept of the known
enrichments of both cell lines (*p < 0.05, Fig 5A and 5B). DMSO background was subtracted from samples
and control values, and data shown as mean (SD) of [(Asamples—ADMSO) / (Acontrol—ADMSO)]*100 of four
independent experiments.
doi:10.1371/journal.pone.0134111.g005
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SLRP anticancer activity, DCN and LUM could play dual microenvironment-dependent roles
in the maintenance of CSCs, inhibiting the growth of epithelial-like proliferative cells, but con-
comitantly promoting the survival and stem-like properties of residual CSC-like, including
TMZ resistance, quiescence, and the maintenance of heterogenic cancer cell phenotypes.
Therefore, our data support microenvironment-dependent protective roles for SLRPs in both
GBM and NB CSC-like.
In addition to the known ECM remodeling and soluble factors (TGF-β, tumor necrosis fac-
tor α, FGF) and membrane receptors (RTKs, Toll-like receptors 2–4) binding activities, we pro-
pose a pivotal role for the SLRP proteoglycans in neurosphere generation, CSC niche
regulation, and the maintenance of a quiescent stem-cell-like phenotype, and consequently in
cell fate and drug resistance of CSC-like. The SLRP expression patterns in NB CSCs may also
indicate that the developmental and oncogenic EMT programs are actively cross-linked.
Further functional and clinical studies should clarify the roles of SLRPs in CSC biology and
in cancer maintenance. More accurate evaluations of the SLRPs in GBM and NB biopsy speci-
mens in terms of the CSC niche are required to determine the clinical potential of SRLPs,
which may inspire niche-targeted cancer therapies in the fight against undifferentiated SRLP+
malignant cancers.
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